[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574171":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":24,"responsibleParty":46,"collaborators":7,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Societa Italiana di Pneumologia","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Francesco B.A. Blasi, MD","Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico","STUDY_CHAIR",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Francesco B.A. Blasi, MD,","CONTACT","0250320627","+39","francesco.blasi@unimi.it",{"name":21,"role":16,"phone":22,"phoneExt":18,"email":23},"Concetta Sirena, Phd","342 0790871","ricerche@sipirs.it",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Via Francesco Sforza 35 20122 Milan Italy","RECRUITING","Milan","Milano","20122","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],12.59836,42.78235,{"lat":37,"lon":36},[40,42,44],{"name":41,"role":16,"phone":17,"phoneExt":18,"email":19},"Francesco B.A. Blasi, Professor, MD, FERS",{"name":43,"role":16,"phone":7,"phoneExt":18,"email":23},"Concetta Sirena",{"name":41,"role":45,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100574171","italian-registry-of-pneumonia-in-immunocompromised-patients-argonaut-100574171",false,"NCT06755814","ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","Community-acquired Pneumonia in Immunosuppressed Adult Patients: Observational, Perspective Study, ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","ARGONAUT","Inclusion Criteria:\n\nHospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:\n\n* AIDS,\n* Aplastic anemia;\n* Asplenia;\n* Hematologic malignancy (e.g., lymphoma\u002Facute or chronic myeloid leukemia\u002Fmultiple myeloma);\n* Chemotherapy within the last 3 months;\n* Neutropenia defined as a white blood cell count less than 500\u002FdL on a complete blood count;\n* Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;\n* Solid organ transplant;\n* Bone marrow transplant;\n* Chronic oral steroid use (\\>10 mg\u002Fday prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \\> 600 mg prednisone);\n* Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \\> 600 mg prednisone;\n* Active malignancy;\n* Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);\n* Lung malignancy with neutropenia\u002Fchemotherapy;\n* Other solid malignancy with neutropenia\u002Fchemotherapy;\n* Other immunodeficiency (including congenital\u002Fgenetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);\n* Primary immunodeficiency.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":59,"type":60},1298,"ESTIMATED","OBSERVATIONAL","This multicentric, prospective study aims at:\n\nevaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.",[64],"Community Acquired Pneumonia (CAP)",[66,67,68,69,70],"CAP","Immunosuppressed","Immunocompromised","Pneumonia","community-acquired pneumonia;","2025-11-14",{"date":73,"type":74},"2025-11-18","ACTUAL",{"date":76,"type":74},"2025-08-11",{"date":78,"type":60},"2028-12",{"name":5,"class":6},1]